TMVRN_NICGU
ID TMVRN_NICGU Reviewed; 1144 AA.
AC Q40392;
DT 26-APR-2004, integrated into UniProtKB/Swiss-Prot.
DT 01-NOV-1996, sequence version 1.
DT 03-AUG-2022, entry version 105.
DE RecName: Full=TMV resistance protein N;
DE EC=3.2.2.6 {ECO:0000255|PROSITE-ProRule:PRU00204};
GN Name=N;
OS Nicotiana glutinosa (Tobacco).
OC Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
OC Spermatophyta; Magnoliopsida; eudicotyledons; Gunneridae; Pentapetalae;
OC asterids; lamiids; Solanales; Solanaceae; Nicotianoideae; Nicotianeae;
OC Nicotiana.
OX NCBI_TaxID=35889;
RN [1]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND ALTERNATIVE SPLICING.
RX PubMed=7923359; DOI=10.1016/0092-8674(94)90283-6;
RA Whitham S., Dinesh-Kumar S.P., Choi D., Hehl R., Corr C., Baker B.J.;
RT "The product of the tobacco mosaic virus resistance gene N: similarity to
RT toll and the interleukin-1 receptor.";
RL Cell 78:1101-1115(1994).
RN [2]
RP NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2), AND DEVELOPMENTAL
RP STAGE.
RX PubMed=10660679; DOI=10.1073/pnas.020367497;
RA Dinesh-Kumar S.P., Baker B.J.;
RT "Alternatively spliced N resistance gene transcripts: their possible role
RT in tobacco mosaic virus resistance.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:1908-1913(2000).
RN [3]
RP MUTAGENESIS OF ASP-46; ILE-63; SER-66; GLN-67; TRP-82; ILE-138; TRP-141;
RP ARG-142; GLY-216; GLY-218; GLY-219; LYS-222; THR-223; ASP-301; ARG-325 AND
RP PRO-619.
RX PubMed=11121079; DOI=10.1073/pnas.97.26.14789;
RA Dinesh-Kumar S.P., Tham W.H., Baker B.J.;
RT "Structure-function analysis of the tobacco mosaic virus resistance gene
RT N.";
RL Proc. Natl. Acad. Sci. U.S.A. 97:14789-14794(2000).
CC -!- FUNCTION: Disease resistance protein. Resistance proteins guard the
CC plant against pathogens that contain an appropriate avirulence protein
CC via a direct or indirect interaction with this avirulence protein. That
CC triggers a defense system including the hypersensitive response, which
CC restricts the pathogen growth.
CC -!- CATALYTIC ACTIVITY:
CC Reaction=H2O + NAD(+) = ADP-D-ribose + H(+) + nicotinamide;
CC Xref=Rhea:RHEA:16301, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC ChEBI:CHEBI:17154, ChEBI:CHEBI:57540, ChEBI:CHEBI:57967; EC=3.2.2.6;
CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00204};
CC PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:16302;
CC Evidence={ECO:0000255|PROSITE-ProRule:PRU00204};
CC -!- INTERACTION:
CC Q40392; B2C7Y6: NRIP1; Xeno; NbExp=3; IntAct=EBI-1804401, EBI-1809509;
CC -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000305}.
CC -!- ALTERNATIVE PRODUCTS:
CC Event=Alternative splicing; Named isoforms=2;
CC Name=1; Synonyms=N, Ns;
CC IsoId=Q40392-1; Sequence=Displayed;
CC Name=2; Synonyms=Ntr, Nl;
CC IsoId=Q40392-2; Sequence=VSP_010126, VSP_010127;
CC -!- DEVELOPMENTAL STAGE: Isoform 1 is more prevalent before and for 3 hours
CC after tobacco mosaic virus (TMV) infection, while isoform 2 is more
CC prevalent 4 to 8 hours after TMV infection.
CC {ECO:0000269|PubMed:10660679}.
CC -!- DOMAIN: The TIR domain mediates NAD(+) hydrolase (NADase) activity.
CC Self-association of TIR domains is required for NADase activity.
CC {ECO:0000255|PROSITE-ProRule:PRU00204}.
CC -!- MISCELLANEOUS: Isoform 1 and isoform 2 are necessary to confer complete
CC resistance to TMV.
CC -!- SIMILARITY: Belongs to the disease resistance NB-LRR family.
CC {ECO:0000305}.
CC ---------------------------------------------------------------------------
CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC ---------------------------------------------------------------------------
DR EMBL; U15605; AAA50763.1; -; Genomic_DNA.
DR PIR; A54810; A54810.
DR AlphaFoldDB; Q40392; -.
DR SMR; Q40392; -.
DR IntAct; Q40392; 1.
DR PRIDE; Q40392; -.
DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell.
DR GO; GO:0043531; F:ADP binding; IEA:InterPro.
DR GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR GO; GO:0050135; F:NAD(P)+ nucleosidase activity; IEA:UniProtKB-EC.
DR GO; GO:0061809; F:NAD+ nucleotidase, cyclic ADP-ribose generating; IEA:UniProtKB-EC.
DR GO; GO:0050832; P:defense response to fungus; IEA:UniProt.
DR GO; GO:0009626; P:plant-type hypersensitive response; IEA:UniProtKB-KW.
DR GO; GO:0007165; P:signal transduction; IEA:InterPro.
DR Gene3D; 1.10.8.430; -; 1.
DR Gene3D; 3.40.50.10140; -; 1.
DR Gene3D; 3.40.50.300; -; 1.
DR Gene3D; 3.80.10.10; -; 2.
DR InterPro; IPR042197; Apaf_helical.
DR InterPro; IPR045344; C-JID.
DR InterPro; IPR044974; Disease_R_plants.
DR InterPro; IPR001611; Leu-rich_rpt.
DR InterPro; IPR003591; Leu-rich_rpt_typical-subtyp.
DR InterPro; IPR032675; LRR_dom_sf.
DR InterPro; IPR002182; NB-ARC.
DR InterPro; IPR027417; P-loop_NTPase.
DR InterPro; IPR000157; TIR_dom.
DR InterPro; IPR035897; Toll_tir_struct_dom_sf.
DR PANTHER; PTHR11017; PTHR11017; 2.
DR Pfam; PF20160; C-JID; 1.
DR Pfam; PF00931; NB-ARC; 1.
DR Pfam; PF01582; TIR; 1.
DR SMART; SM00369; LRR_TYP; 4.
DR SMART; SM00255; TIR; 1.
DR SUPFAM; SSF52200; SSF52200; 1.
DR SUPFAM; SSF52540; SSF52540; 1.
DR PROSITE; PS51450; LRR; 4.
DR PROSITE; PS50104; TIR; 1.
PE 1: Evidence at protein level;
KW Alternative splicing; ATP-binding; Cytoplasm; Hydrolase;
KW Hypersensitive response; Leucine-rich repeat; NAD; Nucleotide-binding;
KW Plant defense; Repeat.
FT CHAIN 1..1144
FT /note="TMV resistance protein N"
FT /id="PRO_0000212781"
FT DOMAIN 10..177
FT /note="TIR"
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT DOMAIN 172..447
FT /note="NB-ARC"
FT REPEAT 597..618
FT /note="LRR 1"
FT REPEAT 620..642
FT /note="LRR 2"
FT REPEAT 643..665
FT /note="LRR 3"
FT REPEAT 834..854
FT /note="LRR 4"
FT REPEAT 859..880
FT /note="LRR 5"
FT REPEAT 882..904
FT /note="LRR 6"
FT ACT_SITE 86
FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00204"
FT BINDING 216..223
FT /ligand="ATP"
FT /ligand_id="ChEBI:CHEBI:30616"
FT /evidence="ECO:0000255"
FT VAR_SEQ 617..652
FT /note="HLPSLRRIDLSWSKRLTRTPDFTGMPNLEYVNLYQC -> KKNNIAEKEGDG
FT ILIEFWGDLQWAFAVSTEDRSQLV (in isoform 2)"
FT /evidence="ECO:0000305"
FT /id="VSP_010126"
FT VAR_SEQ 653..1144
FT /note="Missing (in isoform 2)"
FT /evidence="ECO:0000305"
FT /id="VSP_010127"
FT MUTAGEN 12
FT /note="Y->S,F: Partial loss of resistance."
FT MUTAGEN 46
FT /note="D->H: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 46
FT /note="D->Y: No effect."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 63
FT /note="I->M: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 63
FT /note="I->V: No effect."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 66
FT /note="S->A: No effect."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 67
FT /note="Q->E,K: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 82
FT /note="W->S,A: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 138
FT /note="I->V,F: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 141
FT /note="W->S,A: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 142
FT /note="R->K,S: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 216
FT /note="G->A,E,V,R: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 218
FT /note="G->P: No effect."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 218
FT /note="G->R: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 218
FT /note="G->V,S: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 219
FT /note="G->D: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 219
FT /note="G->V: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 222
FT /note="K->E,N: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 223
FT /note="T->A,N: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 223
FT /note="T->S: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 301
FT /note="D->H,N,Y: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 325
FT /note="R->Y,G: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 619
FT /note="P->A,T: Partial loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
FT MUTAGEN 619
FT /note="P->S: Loss of resistance."
FT /evidence="ECO:0000269|PubMed:11121079"
SQ SEQUENCE 1144 AA; 131486 MW; 1EC5B36D4C4BCBB4 CRC64;
MASSSSSSRW SYDVFLSFRG EDTRKTFTSH LYEVLNDKGI KTFQDDKRLE YGATIPGELC
KAIEESQFAI VVFSENYATS RWCLNELVKI MECKTRFKQT VIPIFYDVDP SHVRNQKESF
AKAFEEHETK YKDDVEGIQR WRIALNEAAN LKGSCDNRDK TDADCIRQIV DQISSKLCKI
SLSYLQNIVG IDTHLEKIES LLEIGINGVR IMGIWGMGGV GKTTIARAIF DTLLGRMDSS
YQFDGACFLK DIKENKRGMH SLQNALLSEL LREKANYNNE EDGKHQMASR LRSKKVLIVL
DDIDNKDHYL EYLAGDLDWF GNGSRIIITT RDKHLIEKND IIYEVTALPD HESIQLFKQH
AFGKEVPNEN FEKLSLEVVN YAKGLPLALK VWGSLLHNLR LTEWKSAIEH MKNNSYSGII
DKLKISYDGL EPKQQEMFLD IACFLRGEEK DYILQILESC HIGAEYGLRI LIDKSLVFIS
EYNQVQMHDL IQDMGKYIVN FQKDPGERSR LWLAKEVEEV MSNNTGTMAM EAIWVSSYSS
TLRFSNQAVK NMKRLRVFNM GRSSTHYAID YLPNNLRCFV CTNYPWESFP STFELKMLVH
LQLRHNSLRH LWTETKHLPS LRRIDLSWSK RLTRTPDFTG MPNLEYVNLY QCSNLEEVHH
SLGCCSKVIG LYLNDCKSLK RFPCVNVESL EYLGLRSCDS LEKLPEIYGR MKPEIQIHMQ
GSGIRELPSS IFQYKTHVTK LLLWNMKNLV ALPSSICRLK SLVSLSVSGC SKLESLPEEI
GDLDNLRVFD ASDTLILRPP SSIIRLNKLI ILMFRGFKDG VHFEFPPVAE GLHSLEYLNL
SYCNLIDGGL PEEIGSLSSL KKLDLSRNNF EHLPSSIAQL GALQSLDLKD CQRLTQLPEL
PPELNELHVD CHMALKFIHY LVTKRKKLHR VKLDDAHNDT MYNLFAYTMF QNISSMRHDI
SASDSLSLTV FTGQPYPEKI PSWFHHQGWD SSVSVNLPEN WYIPDKFLGF AVCYSRSLID
TTAHLIPVCD DKMSRMTQKL ALSECDTESS NYSEWDIHFF FVPFAGLWDT SKANGKTPND
YGIIRLSFSG EEKMYGLRLL YKEGPEVNAL LQMRENSNEP TEHSTGIRRT QYNNRTSFYE
LING
